Fortrea Holdings Inc.
Fortrea Holdings Inc. is a standalone contract research organization created from Labcorp’s drug development business in 2023. It designs and runs clinical development programs for pharmaceutical, biotechnology, and medical device customers, spanning phase I through IV trials, clinical pharmacology, and consulting services.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueEnd-to-end planning, execution, and management of clinical trials across phases I-IV.
Specialized early-stage development services supporting dose selection and human pharmacology studies.
Dedicated functional outsourcing teams that support specific sponsor functions and workflows.
Protocol, regulatory, operational, and development strategy support for sponsors.
Customers
Fortrea sells to pharmaceutical, biotechnology, and medical device companies that need outsourced clinical development execution and scientific expertise. Its customer base includes small/emerging biotech sponsors as well as mid-size and large global life sciences companies, with demand driven by the need to run trials faster, across more geographies, and with flexible engagement models.
Buy full-service and functional outsourcing for late-stage and global clinical programs to accelerate development.
Buy flexible, high-touch clinical development and pharmacology support to advance pipelines with limited internal infrastructure.
Buy clinical trial management and consulting for regulated device development and evidence generation.
Buy scientific, regulatory, and operational support to design studies and execute trials efficiently.
Buy scalable global delivery, FSP teams, and hybrid structures for complex multi-country programs.
Strategy
Fortrea’s strategy centers on commercial excellence, operational excellence, and financial excellence, with an emphasis on winning repeat business and expanding its relevance with sponsors. It is also focused on using its global scale and therapeutic expertise to deliver flexible models, strengthen customer relationships, and improve margins through better execution and portfolio mix.
Clinical CRO revenue depends on winning and retaining sponsor programs, which can be delayed or reduced in scope.
Better study delivery, site performance, and centralized processing can improve profitability in a service-heavy model.
Broader expertise and global reach help win complex trials and support customer geographic priorities.
Geography
Q1/2026Fortrea operates in approximately 100 countries and says it supports trials in all major pharmaceutical and biotechnology markets. Its workforce is distributed across the Americas, EMEA, and Asia-Pacific, with the largest share in Asia-Pacific, which reflects the global nature of clinical trial site access, patient recruitment, and regulatory execution.
Share of the revenue the company reports by geography.
Risks
Fortrea’s results depend on sponsor funding, trial award timing, patient recruitment, and investigator availability, so delays or cancellations can quickly affect revenue. Its global operating model also exposes it to foreign exchange, regulatory, geopolitical, and customer concentration risks, while the post-spin structure and acquisition activity add integration and execution risk.
- Delayed or lost net new business awardsImpact: HighLikelihood: Medium
CRO revenue depends on winning sponsor programs; delays or cancellations directly reduce backlog and utilization.
Exposure: Clinical Services pipeline and contract conversion
- Patient recruitment and investigator access constraintsImpact: HighLikelihood: Medium
Trials cannot progress without suitable sites and enrolled patients, which can push out timelines and revenue recognition.
Exposure: Phase I-IV trial execution
- International operating complexityImpact: MediumLikelihood: Medium
Operating in about 100 countries creates exposure to local regulation, currency movements, and geopolitical disruptions.
Exposure: Global delivery footprint
- Integration and acquisition executionImpact: MediumLikelihood: Medium
Strategic transactions can create disruption, goodwill impairment risk, and operational complexity if not integrated well.
Exposure: M&A and divestiture activity
- Customer and therapeutic concentrationImpact: Medium
A small number of large sponsors or therapeutic areas can disproportionately affect demand and margins if programs change.
Exposure: Sponsor mix and therapeutic portfolio
Accounting
Judgemental itemsRevenue timing depends on study milestones, progress, and pass-through costs, which can shift quarterly results.
Impact: Affects reported growth, margins, and comparability across periods
The sale of the Enabling Services segment changes the revenue and cost base and can distort trend analysis.
Impact: Impacts year-over-year comparability and segment analysis
The company carries significant goodwill and must test it annually or when conditions change.
Impact: Could create material noncash charges if fair value declines
The $300 million receivables facility affects liquidity presentation and balance sheet receivables.
Impact: Influences working capital, cash flow, and leverage optics
Similar listed companies
Publicly listed companies with a comparable business focus.
Forte Biosciences, Inc.
Pharmaceutical Preparations
Medpace Holdings, Inc.
MEDP · Services-Commercial Physical & Biological Research
Medpace Holdings is a contract research organization that runs outsourced clinical development programs for biotechnology, pharmaceutical, and medical device companies.
IQVIA Holdings, Inc
IQV · Services-Commercial Physical & Biological Research
Fortress Biotech, Inc.
FBIOP · Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Kyntra Bio, Inc
KYNB · Pharmaceutical Preparations
Last updated: 24/09/2026